摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,6-dichloro-3-aza-bicyclo[3,1,0]hexane-2,3-dicarboxylic acid di-tert-butyl ester | 394735-34-3

中文名称
——
中文别名
——
英文名称
6,6-dichloro-3-aza-bicyclo[3,1,0]hexane-2,3-dicarboxylic acid di-tert-butyl ester
英文别名
ditert-butyl (1S,2S,5R)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate
6,6-dichloro-3-aza-bicyclo[3,1,0]hexane-2,3-dicarboxylic acid di-tert-butyl ester化学式
CAS
394735-34-3
化学式
C15H23Cl2NO4
mdl
——
分子量
352.258
InChiKey
BCRDCQAHKIZEDF-GUBZILKMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    403.9±45.0 °C(Predicted)
  • 密度:
    1.27±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.87
  • 拓扑面积:
    55.8
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    6,6-dichloro-3-aza-bicyclo[3,1,0]hexane-2,3-dicarboxylic acid di-tert-butyl ester 在 sodium carbonate 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 24.0h, 生成 (1S,2S,5R)-3-(tert-butoxycarbonyl)-6,6-dichloro-3-azabicyclo[3.1.0]hexane-2-carboxylic acid
    参考文献:
    名称:
    [EN] FUSED PYRROLIDINE COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY VIRAL INFECTIONS
    [FR] COMPOSÉS PYRROLIDINES CONDENSÉS ET COMPOSITIONS POUR LE TRAITEMENT D'INFECTIONS VIRALES RESPIRATOIRES
    摘要:
    Provided herein are antiviral compounds of Formula P-I or pharmaceutically acceptable salts, N-oxides, prodrugs, hydrates, or solvates thereof, pharmaceutical compositions containing the same, methods for their use, and methods for their preparation.
    公开号:
    WO2023116734A1
  • 作为产物:
    参考文献:
    名称:
    [EN] FUSED PYRROLIDINE COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY VIRAL INFECTIONS
    [FR] COMPOSÉS PYRROLIDINES CONDENSÉS ET COMPOSITIONS POUR LE TRAITEMENT D'INFECTIONS VIRALES RESPIRATOIRES
    摘要:
    Provided herein are antiviral compounds of Formula P-I or pharmaceutically acceptable salts, N-oxides, prodrugs, hydrates, or solvates thereof, pharmaceutical compositions containing the same, methods for their use, and methods for their preparation.
    公开号:
    WO2023116734A1
点击查看最新优质反应信息

文献信息

  • [EN] CYCLOBUTENEDIONE GROUPS-CONTAINING COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE<br/>[FR] GROUPES CYCLOBUTENEDIONE CONTENANT DES COMPOSES SERVANT D'INHIBITEURS A LA SERINE PROTEASE NS3 DU VIRUS DE L'HEPATITE C
    申请人:SCHERING CORP
    公开号:WO2005085197A1
    公开(公告)日:2005-09-15
    The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    本发明公开了具有HCV蛋白酶抑制活性的新化合物,以及制备这种化合物的方法。在另一实施方式中,本发明公开了包含这种化合物的药物组合物,以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
  • [EN] NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS<br/>[FR] NOUVEAUX CETOAMIDES A P4 CYCLIQUES EN TANT QU'INHIBITEURS DE LA NS3 SERINE PROTEASE DU VIRUS DE L'HEPATITE C
    申请人:SCHERING CORP
    公开号:WO2005085242A1
    公开(公告)日:2005-09-15
    The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    本发明公开了具有HCV蛋白酶抑制活性的新化合物,以及制备这种化合物的方法。在另一实施方式中,该发明公开了包含这种化合物的药物组合物,以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
  • NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
    申请人:Saksena Anil K.
    公开号:US20110117057A1
    公开(公告)日:2011-05-19
    The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    本发明披露了具有HCV蛋白酶抑制活性的新化合物,以及制备这些化合物的方法。在另一种实施方式中,本发明披露了包含这些化合物的制药组合物,以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
  • [EN] NOVEL COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE<br/>[FR] NOUVEAUX COMPOSES EN TANT QU'INHIBITEURS DE LA SERINE PROTEASE NS3 DU VIRUS DE L'HEPATITE C
    申请人:SCHERING CORP
    公开号:WO2005087725A3
    公开(公告)日:2005-10-27
  • [EN] COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE<br/>[FR] NOUVEAUX COMPOSES EN TANT QU'INHIBITEURS DE LA PROTEASE SERINE NS3 DU VIRUS DE L'HEPATITE C
    申请人:SCHERING CORP
    公开号:WO2005087721A3
    公开(公告)日:2005-11-10
查看更多